Journal: BMC Cancer

Article Title: Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study

doi: 10.1186/s12885-018-4880-x

Figure Lengend Snippet: Summary of tissue expression of Sp17 by type of epithelium or neoplasm

Article Snippet: Human sperm surface protein Sp17 ELISA kits (Cusabio Biotech, Wuhan, China) were used to measure the Sp17 serum concentrations.

Techniques: Expressing, Staining

Journal: BMC Cancer

Article Title: Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study

doi: 10.1186/s12885-018-4880-x

Figure Lengend Snippet: Representative Sp17 immunohistochemistry staining in ovarian tissue of serous histology. Examples of Sp17 protein expression in benign and malignant ovarian tissue demonstrating both positive and negative staining and intensity of Sp17 staining are shown. a ) Serous cystadenoma showing tissue staining positive with strong expression of Sp17 in ciliated cells. b ) Serous borderline tumor showing strong Sp17 expression. c ) Grade 1 serous adenocarcinoma negative for Sp17 expression. d ) Grade 1 serous adenocarcinoma showing strong Sp17 expression. e ) Grade 3 serous adenocarcinoma negative for Sp17. f ) Grade 3 serous adenocarcinoma demonstrating strong Sp17 staining. Stroma surrounding epithelial cells is negative

Article Snippet: Human sperm surface protein Sp17 ELISA kits (Cusabio Biotech, Wuhan, China) were used to measure the Sp17 serum concentrations.

Techniques: Immunohistochemistry, Staining, Expressing, Negative Staining

Journal: BMC Cancer

Article Title: Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study

doi: 10.1186/s12885-018-4880-x

Figure Lengend Snippet: Univariate and multivariable analysis of Sp17 tissue expression among epithelial ovarian carcinoma specimens

Article Snippet: Human sperm surface protein Sp17 ELISA kits (Cusabio Biotech, Wuhan, China) were used to measure the Sp17 serum concentrations.

Techniques: Expressing, Biomarker Discovery

Journal: BMC Cancer

Article Title: Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study

doi: 10.1186/s12885-018-4880-x

Figure Lengend Snippet: Sp17 RNA expression is upregulated in borderline ovarian cancers. Sp17 mRNA expression was analyzed from two publically available patient tumor Oncomine datasets. a Sp17 mRNA levels are significantly increased in borderline ovarian serous adenocarcinoma when compared to ovarian serous adenocarcinoma ( p < 0.001) in Anglesio et al. dataset . b Sp17 mRNA levels are significantly increased in borderline ovarian serous adenocarcinoma when compared to ovarian adenocarcinoma (p < 0.001) in Tothill et al. dataset ( c ) No significant difference in Sp17 expression is seen between grades of ovarian adenocarcinoma ( p = 0.42) . Box encompasses 25th–75th percentile, solid black line indicates median and error bars indicate range. Numbers in parentheses indicate number of cases included in the analysis

Article Snippet: Human sperm surface protein Sp17 ELISA kits (Cusabio Biotech, Wuhan, China) were used to measure the Sp17 serum concentrations.

Techniques: RNA Expression, Expressing

Journal: BMC Cancer

Article Title: Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study

doi: 10.1186/s12885-018-4880-x

Figure Lengend Snippet: Median Sp17 serum concentration by type of ovarian neoplasm

Article Snippet: Human sperm surface protein Sp17 ELISA kits (Cusabio Biotech, Wuhan, China) were used to measure the Sp17 serum concentrations.

Techniques: Concentration Assay

Journal: BMC Cancer

Article Title: Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study

doi: 10.1186/s12885-018-4880-x

Figure Lengend Snippet: Serum Sp17 concentration compared to histology and tissue expression. a Distribution of serum Sp17 concentration in benign ovarian neoplasms, borderline ovarian tumors (BOTs), and epithelial ovarian carcinomas (EOCs). The serum concentration of Sp17 is plotted in standard box and whisker plots on a log 10 scale by histology. No significant difference was found between the serum Sp17 concentration when comparing benign ovarian neoplasms, BOTs, and EOCs. ANOVA test showed that there was a significant difference (p < 0.001) in serum Sp17 concentration among the four main histologic subtypes of EOC: serous, mucinous, endometrioid, and clear cell. Box (interquartile range) encompasses 25th–75th percentile, solid black line indicates median and the whiskers indicate the lowers and highest data values that are still within the 25th and 75th percentile value plus 1.5 times the interquartile range, respectively. The outliers are represented as separate data points. Numbers in parentheses indicate number of cases included in the analysis. b Distribution of serum Sp17 concentration by tissue expression of Sp17. There were 65 patients with both serum and ovarian tissue available, which included benign, borderline, and malignant ovarian neoplasms. The ovarian tissue underwent immunohistochemical (IHC) staining for Sp17 and any expression was considered a positive result. The matching sera for these patients were analyzed for Sp17 concentration using ELISA and the concentration converted to a log 10 scale and represented here in box and whisker plots. There was a significant difference in serum Sp17 levels between IHC positive neoplasms compared to IHC negative neoplasms ( p = 0.027), with IHC positive neoplasms showing higher SP17 levels. Box (interquartile range) encompasses 25th–75th percentile, solid black line indicates median and the whiskers indicate the range. Numbers in parentheses indicate number of cases included in the analysis

Article Snippet: Human sperm surface protein Sp17 ELISA kits (Cusabio Biotech, Wuhan, China) were used to measure the Sp17 serum concentrations.

Techniques: Concentration Assay, Expressing, Whisker Assay, Immunohistochemical staining, Immunohistochemistry, Enzyme-linked Immunosorbent Assay

Journal: Nature neuroscience

Article Title: NG2 glia protect against prion neurotoxicity by inhibiting microglia-to-neuron prostaglandin E2 signaling.

doi: 10.1038/s41593-024-01663-x

Figure Lengend Snippet: Fig. 7 | PGE2 enhances prion neurotoxicity mainly through the EP4 receptor (Ptger4). a,b, Live-cell imaging (a) and quantitative analysis (b) of chronically prion-infected HovS cells expressing control (Ctrl) transgene or one of the four PGE2 receptors (Ptger1–4). Effects of PGE2 treatment on prion-induced cell toxicity were measured with the ratio of GFP signals under the PGE2 condition against the DMSO condition; n = 4 independent experiments. Data are presented as mean ± s.e.m. One-way ANOVA with Benjamini–Hochberg FDR adjustment for multiple comparisons: P < 0.0001 (Ptger1 versus Ctrl); P = 0.2246 (Ptger2 versus Ctrl); P = 0.3351 (Ptger3 versus Ctrl); P < 0.0001 (Ptger4 versus Ctrl). c, Immunofluorescence of NeuN, Map2 and Tau showing cellular damage of prion- infected primary neurons treated with different concentrations of Ptger4 agonist L902688. d, Quantification of neuronal density as well as Map2-positive and Tau positive areas shown in c; n = 6 independent experiments. Data are presented as

Article Snippet: The following primary antibodies were used: rabbit polyclonal antibody against NG2 (1:500, a gift from W. Stallcup), rabbit monoclonal antibody against NeuN (1:1,000, Abcam, cat. no. ab177487), rabbit polyclonal antibody against Iba1 (1:500, Wako, cat. no. 019-19741), rat monoclonal antibody against Cd68 (1:200, BioRad, cat. no. MCA1957), rabbit polyclonal antibody against Map2 (1:200, Biolegend, cat. no. 840601), mouse monoclonal antibody against Tau (1:200, ThermoFisher Scientific, cat. no. MN1010), chicken polyclonal antibody against NeuN (1:1,000, Merck, cat. no. ABN91), mouse monoclonal antibody against Cox2 (1:200, Santa Cruz, cat. no. sc-166475), mouse monoclonal antibody against Ptges (1:200, Santa Cruz, cat. no. sc-365844), rabbit polyclonal antibody against EP1 (1:200, Bioss Antibodies, cat. no. BS-6316R), rabbit monoclonal antibody against EP2 (1:200, Abcam, cat. no. ab167171), rabbit polyclonal antibody against EP3 (1:200, Cayman Chemical, cat. no. 101760) and mouse monoclonal antibody against EP4 (1:200, ProteinTech, cat. no. 66921-1-Ig).

Techniques: Live Cell Imaging, Infection, Expressing, Control, Immunofluorescence